WAYNE, N.J., May 25, 2018 — Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study.

Patients who required permanent pacemakers (PPMs) after transcatheter aortic valve replacement (TAVR) demonstrated lower survival rates and higher comorbidity burdens over a multiyear follow-up. However, they didn’t accumulate significantly greater healthcare costs, according to a study published online May 25 in JAMA Network Open.

At just 5-months-old, Luke Pilkinton has survived what most would hope never to experience in a lifetime. He was born with hypoplastic left heart syndrome—a rare and deadly congenital defect, that affects 960 babies born in the U.S. every year.

About 10 percent of people who suffer a type 1 myocardial infarction (MI) at age 50 or younger use cocaine or marijuana, according to a new study, and these individuals showed double the risk of cardiovascular or all-cause death over extended follow-up.

Triggering a shift in fluids from the chest to the abdomen by blocking the splanchnic nerves has the potential to relieve acute heart failure symptoms, according to research presented May 26 at Heart Failure 2018 and published simultaneously in Circulation.

Middle-aged men who eat higher amounts of protein are associated with a slightly elevated risk for heart failure (HF) than those who eat less protein, according to a new study published in Circulation: Heart Failure on May 29. There is a limited amount of information regarding how diets high in protein impact men’s HF risk.

Heart failure patients who were given instructions on how to use a Nintendo Wii device—which incorporates physical activity into video gaming—improved their exercise capacity and quality of life more than counterparts who were simply advised to exercise 30 minutes per day.

MILFORD, Mass. — May 29, 2018 — RenalGuard Solutions™, Inc., a medical device company focused on innovative fluid management technologies for the cardiac and vascular markets, today announced new clinical study results demonstrating the feasibility of using RenalGuard®-Guided Diuretic Therapy to optimize fluid management in Acute Decompensated Heart Failure (ADHF) patients while alleviating related symptoms.